NCT05015920View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants

NACompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 10, 2021

Primary Completion Date

August 23, 2024

Study Completion Date

December 31, 2024

Conditions
Hematologic Diseases
Interventions
GENETIC

BD211 Drug Product

Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.

Trial Locations (1)

650000

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming

All Listed Sponsors
collaborator

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

OTHER

lead

Shanghai BDgene Co., Ltd.

INDUSTRY